

NCIC CLINICAL TRIALS GROUP

BREAST

DISEASE SITE COMMITTEE MEETING AGENDADelta Chelsea Hotel, Toronto, Ontario

Room: Mountbatten

Saturday, April 28, 2012: 8:30 AM – 4:15 PM

CO-CHAIRS: T. WHELAN / K. GELMON

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with breast cancer both in the adjuvant and the metastatic setting in Canada
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to breast cancer
- To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group
- To place the results of clinical studies in the context of ongoing care of patients in Canada with breast cancer and to translate these results into clinical practice
- To provide a learning environment supportive to new investigators

8:30 am **Welcome, Introductions, Comments -**

T.Whelan/K. Gelmon

8:40 am **Closed Trials:**

- | | |
|---|-------------|
| • MA.17R (Letrozole vs Placebo after AI) | W.Parulekar |
| • MA.20 (Regional Radiation Therapy in Early Breast Cancer) | T. Whelan |
| • MA.21 (Adjuvant Chemotherapy) | M.Burnell |

9:10 am **Open Trials:**

- | | |
|---|------------|
| • MA.31 (Lapatinib vs Trastuzumab in Metastatic) | K. Gelmon |
| • MA.32 (Metformin + NSABP Fatigue MA.32F + CALGB Breast Density) | P. Goodwin |
| • MA.33 (TROG 07.01: Non-low risk DCIS of breast) | M.Akra |
| • MA.34 (BIG 4-11/APHINITY/Pertuzumab) | S.Dent |

9:50 am **IND Trials:**

- | | |
|--|----------|
| • IND.197 (Phase II Foretinib in ER/PgR & HER2 Neg Recurrent/Metastatic) | D.Rayson |
| • IND.198 (Phase I/II Foretinib & Lapatinib in HER2 + Metastatic) | S. Chia |

10:15 am Coffee Break

10:30 am **Invited Speaker***“Clinical Trials in Canada: Current and Changing Landscape”*Elizabeth Eisenhauer
Director, NCIC CTG IND Programme11:00 am **Updates from Working Group Sessions**

- Report from NeoAdjuvant/Locally Advanced Breast Cancer Working Group M.Basik
- Report from Working Group for Novel Targets in Breast Cancer P.Bedard
- Tissue / Serum Collections / Correlative Trials L.Shepherd

12:00 Noon Lunch.....1:30 pm **Invited Speaker***“Translational Pathology in Breast Cancer: The Present and the Future”*John Bartlett
Director of Transformative Pathology, OICR2:00 pm **CTSU Trials – Open and Closed:**

- MAC.4 (IBCSG 24-02/SOFT) B. Walley
- MAC.5 (IBCSG 25-02/TEXT) B. Walley
- MAC.7 (SWOG S0226 – AI vs AI+F) T.Vandenberg
- MAC.9 (SWOG S0307 – Bisphosphonate) M.Clemons
- MAC.11 (SWOG 0221 – Adj chemo, high risk) L.Shepherd/J.Latreille
- MAC.12 (TAILORx) K.Pritchard
- MAC.13 (ALTTO) K.Pritchard
- MAC.14 (ECOG 2108 – Local Therapy in Stage IV) M.Basik
- MAC.15 (SWOG S1007 – Responder Trial) S.Chia/B.Dhesy

3:15 pm **Trial Proposals:**

- MA.30 (Faslodex in Adjuvant Breast Cancer) K.Gelmon/K.Pritchard/S.Verma
- Neo-Faslodex K.Gelmon
- Low Risk DCIS E.Rakovitch/T.Whelan
- Reolysin (Phase II: Reolysin /weekly paclitaxel, advanced/metastatic) K.Gelmon
- Abraxane (Michelangelo Abraxane Proposal) K.Gelmon
- Everolimus K.Gelmon
- Foretinib D.Rayson
- A11201 (Telephone Intervention/Weight Loss/IDFS/Obesity) P.Goodwin/R.Segal

4:00 pm **Closing Remarks and Adjournment***Brief Executive Meeting*